Work

CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor

Year: 2018

Type: article

Source: Biochemical Pharmacology

DOI: 10.1016/j.bcp.2018.10.012

Authors: Junjie Zhu, Pengcheng Wang, Feng Li, Jie Lu, Amina I. Shehu, Wen Xie, Deborah McMahon, Xiaochao Ma

Institutions: University of Pittsburgh, Baylor College of Medicine

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: G3607151935, Pharmacoenhancers for antiretroviral therapy: safety and future development, G7619879180, Mechanisms of adverse effects of anti-tuberculosis drugs

OpenAlex ID: W2895863636

FWCI: 0.975

Cites: 38

Cited by: 12

Related to: 10